Supreme Court Denies Cert. In Lilly V. Sun
nts/BIO_amicus_brief_Sun_v_Lilly.pdf”>(611 F.3d 1381 (Fed. Cir. 2010) and concluded that the majority of the Fed. Cir. got this one wrong – the court voted 5-4 to deny rehearing en banc. Although Lilly had prosecution strategies available that would have avoided invalidation of their patent on a newly discovered use of gemcitabine, Lilly picked the wrong one. All practitioners should re-read this decision so as to not fall into the same trap. Ironically, this is an appeal in which Supreme Court review likely would have helped the patent system.